Danaher

Danaher Foundation has committed $1 million to support Ebola outbreak relief efforts in Central Africa.

DHR narrative: earnings call content Q1 2026 Earnings Call Transcript (Q1 2026)

Danaher Corp. stock underperformed its competitors on Thursday despite daily gains.

Danaher's stock has declined 22% this year due to the $9.9 billion Masimo acquisition, which has introduced concerns about patent disputes and debt, yet the company's Q1 2026 earnings beat estimates and it raised its FY2026 EPS guidance, indicating a potential investment opportunity.

Danaher's stock has dropped over 22% this year due to concerns surrounding its $9.9 billion Masimo acquisition, which led to significant debt and patent dispute issues, despite the company reporting Q1 FY2026 revenue of $5.95 billion and maintaining its FY2026 EPS guidance.

Danaher's stock decline of over 22% this year, primarily due to its $9.9 billion Masimo acquisition, may represent an attractive entry point for investors given the company's maintained FY2026 EPS guidance and growth in equipment orders driven by a multiyear manufacturing investment cycle.

Danaher, as a mid-cap biotech, has the potential to become a significant competitive threat to larger pharmaceutical companies like Eli Lilly and Novo Nordisk.

Danaher has scheduled its Second Quarter 2026 Earnings Conference Call.